{"entity":{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of atezolizumab and fludeoxyglucose F-18 (FDG) in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","summary":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT04214262 by National Cancer Institute (NCI), with a registry enrolment figure of 415 participants, started 2020-08-13 and due to reach its primary completion in 2024-08-24. Interventions recorded: Atezolizumab; Biospecimen Collection; Computed Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy. Conditions listed: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8. Primary outcome: Overall survival. Lung eligibility wording from the registry: \"* Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04214262","url":"https://clinicaltrials.gov/study/NCT04214262"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["atezolizumab","fludeoxyglucose-f18"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04214262","phase":"3","setting":"A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC","sponsor":"National Cancer Institute (NCI)","enrolled":415,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04214262/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}